Bagaimana Langkah Undi Pengguguran Kandungan Arizona Mempengaruhi Perlumbaan Presiden Berita

Bagaimana Langkah Undi Pengguguran Kandungan Arizona Mempengaruhi Perlumbaan Presiden

August 14, 2024
(SeaPRwire) - Pengundi Arizona akan membuat keputusan pada bulan November sama ada untuk mengukuhkan hak untuk pengguguran kandungan dalam perlembagaan negeri - satu langkah di negeri ayun kunci yang boleh memberi kesan kepada pilihan raya presiden yang penuh gejolak dan bersejarah. Pejabat setiausaha negeri Arizona mengesahkan kepada TIME bahawa langkah itu akan muncul dalam kertas undi pada pilihan raya bulan November selepas ia disahkan pada hari Isnin mengenai 577,971 tandatangan - jauh melebihi jumlah yang diperlukan untuk meletakkan inisiatif itu dalam kertas undi. Dawn Penich, pengarah komunikasi untuk gabungan yang menyokong inisiatif itu, Arizona for Abortion Access, berkata kumpulan itu menyerahkan jumlah tandatangan tertinggi oleh inisiatif warga dalam sejarah negeri: lebih daripada 820,000. Gabungan itu, yang termasuk organisasi hak reproduktif seperti American Civil Liberties Union of Arizona dan Planned Parenthood Advocates of Arizona, menyambut baik berita itu. “Kita terus maju dengan inisiatif kertas undi kita dan mendapatkan sokongan sebanyak yang kita sudah peroleh menunjukkan bahawa penduduk Arizona sudah jemu melihat hak mereka tertakluk kepada kehendak politik sesiapa sahaja yang mungkin berada di badan perundangan atau sesiapa sahaja yang mungkin berada di mahkamah kita, dan mereka ingin menyelesaikan perkara ini sekali gus untuk diri mereka sendiri melalui proses inisiatif warga ini,” kata Chris Love, jurucakap kempen gabungan itu. Arizona kini melarang pengguguran kandungan selepas 15 minggu kehamilan. Undang-undang itu, yang ditandatangani pada tahun 2022, termasuk pengecualian untuk kecemasan perubatan. Langkah kertas undi bulan November, Cadangan 139, akan membenarkan pengguguran kandungan sehingga janin boleh hidup di luar rahim, yang biasanya sekitar minggu ke-24 kehamilan. Ia juga akan termasuk pengecualian selepas itu jika nyawa orang hamil dalam bahaya atau untuk melindungi kesihatan fizikal atau mental individu. Ia akan dalam perlembagaan negeri dan akan menghalang negeri daripada mengharamkan atau mengehadkan akses kepada prosedur itu sebelum boleh hidup. Negeri-negeri termasuk dan sebelum ini telah meluluskan langkah serupa. Mereka yang menentang langkah itu telah mengatakan ia terlalu melampau, dengan alasan bahawa terlalu luas dan akan membenarkan orang ramai untuk menamatkan kehamilan yang boleh hidup. Mempunyai inisiatif pengguguran kandungan dalam kertas undi pada bulan November boleh memberi kesan politik di luar hak reproduktif di Arizona. Dalam kempen presiden, ia adalah perbezaan utama antara , yang memainkan peranan penting dalam mesej Pentadbiran Biden mengenai hak reproduktif, dan , yang melantik tiga Hakim Mahkamah Agung yang mengundi untuk membatalkan Roe v. Wade. Yang lain Demokrat telah menjadikannya fokus utama kempen 2024 mereka, dan negeri-negeri termasuk Colorado, Florida, Maryland, Nevada, dan South Dakota sedang mengkaji semula hak pengguguran kandungan tahun ini. Interaksi isu itu dengan perlumbaan politik dan bagaimana ia memberi kesan kepada jumlah pengundi boleh menjadi penentu khususnya di Arizona, salah satu negeri medan pertempuran yang paling penting dalam pilihan raya 2024. “Arizona adalah negeri ayun; hasil pilihan raya kita biasanya tipis, tipis,” kata Samara Klar, profesor sains politik di University of Arizona. “Kita melihat margin kemenangan kecil dalam pilihan raya yang sangat tinggi, dan terus terang, dalam pilihan raya tempatan juga. Oleh itu, mempunyai sesuatu dalam kertas undi yang akan menggerakkan pengundi untuk keluar mengundi adalah sangat, sangat penting.” Dalam inisiatif kertas undi lain yang telah dibentangkan kepada pengundi sejak Mahkamah Agung A.S. menghapuskan hak perlembagaan untuk pengguguran kandungan pada tahun 2022, rakyat Amerika secara amnya dan isu itu biasanya telah meningkatkan sokongan kepada Demokrat. “Mempunyai pengguguran kandungan dalam kertas undi adalah membantu bagi Demokrat kerana ia menggerakkan jenis orang yang akan menyokong calon Demokrat,” kata Klar. Beberapa tinjauan pendapat menunjukkan sokongan untuk hak pengguguran kandungan di kalangan penduduk Arizona. Pada bulan Mac, Klar bekerjasama dengan YouGov untuk melakukan terhadap 800 pengundi berdaftar Arizona. Lebih daripada 40% berkata keputusan pengguguran kandungan harus diserahkan kepada wanita dan doktornya, manakala kira-kira 25% menyokong larangan pengguguran kandungan hampir sepenuhnya. pada bulan Mei mendapati bahawa 65% pengundi berkemungkinan di Arizona berkata mereka akan mengundi “ya” pada langkah kertas undi yang mewujudkan hak perlembagaan untuk pengguguran kandungan di negeri ini; 21% berkata mereka akan mengundi menentangnya. Dasar pengguguran kandungan di Arizona agak tidak menentu sejak keputusan Mahkamah Agung A.S. dalam dua tahun yang lalu. Pada bulan April, Mahkamah Agung Arizona undang-undang 1864 yang hanya membenarkan pengguguran kandungan untuk menyelamatkan nyawa orang hamil, tanpa pengecualian untuk rogol atau inses. Badan perundangan yang dikawal oleh Republikan kemudian undang-undang itu, meninggalkan undang-undang 2022 yang melarang pengguguran kandungan selepas 15 minggu. “Terdapat banyak kekeliruan mengenai status undang-undang di Arizona,” kata Love. “Memastikan hak ini dalam perlembagaan memberi pengundi Arizona kepastian yang mereka perlukan untuk memahami apa hak reproduktif mereka dan, sekali lagi, mengembalikan perkara itu ke tangan mereka sendiri dan membuat keputusan penjagaan kesihatan peribadi dengan keluarga dan penyedia perubatan mereka.” Dan ketika pengundi Arizona menuju ke peti undi, inisiatif pengguguran kandungan “pasti boleh memberi perbezaan” dalam perlumbaan presiden, kata Klar. “Ini adalah negeri yang ketat, isu yang menonjol, dan isu yang sangat menggerakkan.”Artikel ini disediakan oleh pembekal kandungan pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberi sebarang waranti atau perwakilan berkaitan dengannya. Sektor: Top Story, Berita Harian SeaPRwire menyampaikan edaran siaran akhbar secara masa nyata untuk syarikat dan institusi, mencapai lebih daripada 6,500 kedai media, 86,000 penyunting dan wartawan, dan 3.5 juta desktop profesional di seluruh 90 negara. SeaPRwire menyokong pengedaran siaran akhbar dalam bahasa Inggeris, Korea, Jepun, Arab, Cina Ringkas, Cina Tradisional, Vietnam, Thai, Indonesia, Melayu, Jerman, Rusia, Perancis, Sepanyol, Portugis dan bahasa-bahasa lain.
More
“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates JCN Newswire

“LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates

August 14, 2024
TOKYO and CAMBRIDGE, Mass., Aug 14, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (lecanemab) for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD), the population in which treatment was initiated in clinical trials.LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques, thereby reducing both Aβ protofibrils and Aβ plaques in the brain. LEQEMBI is the first approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism. LEQEMBI is also approved in the U.S., Japan, China, South Korea, Hong Kong, and Israel, and is being marketed in the U.S., Japan, and China.LEQEMBI’s approval is based on the large global Phase 3 Clarity AD study. In the Clarity AD study, LEQEMBI met its primary endpoint and all key secondary endpoints with statistically significant results.(1),(2) In the UAE, it is reported that 4.09% of those over 60 years old have dementia.(3) AD is considered the most common cause of dementia, typically accounting for 60-70% of cases.(4)Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. Biogen will commercialize LEQEMBI in the UAE.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.(5) Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.(6) About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).LEQEMBI’s FDA approval was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results.1,2 The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with LEQEMBI and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More

Mpox Diisytiharkan Sebagai Kecemasan Kesihatan di Afrika

August 14, 2024
(SeaPRwire) - Wabak cacar monyet di Afrika telah diisytiharkan sebagai kecemasan kesihatan awam di seluruh benua, ketika badan penasihat kesihatan utama wilayah itu menggunakan kuasa ini buat pertama kalinya ketika bergerak untuk menggerakkan sumber. Pengisytiharan itu akan mendorong negara-negara di rantau ini untuk berkongsi maklumat tepat pada masa mengenai penyebaran cacar monyet dengan Pusat Kawalan dan Pencegahan Penyakit Afrika, membantu ia memanfaatkan bantuan kewangan dengan lebih baik, kata Jean Kaseya, ketua pengarah agensi yang berpusat di Addis Ababa, pada Selasa. “Hari ini saya komited kepada anda bahawa warga Afrika akan memimpin perjuangan ini dengan setiap sumber yang ada pada kita,” katanya pada taklimat media maya. “Kami akan bekerjasama dengan kerajaan, rakan kongsi antarabangsa dan komuniti tempatan untuk memastikan setiap orang Afrika, dari bandar-bandar yang sibuk hingga ke kawasan terpencil, dilindungi.” Sejenis cacar monyet telah merebak ke sekurang-kurangnya enam negara Afrika, menjangkiti kira-kira 15,000 dan membunuh lebih daripada 500 di Republik Demokratik Congo tahun ini sahaja. Varian itu pertama kali dilaporkan di DRC kurang daripada 12 bulan yang lalu. Walaupun vaksin cacar monyet tersedia, hanya sedikit yang sampai ke Afrika—satu-satunya benua di mana penyakit itu endemik. Pada kira-kira $100 setiap dos, vaksin kini sangat mahal, kata Kaseya sebelum ini. Afrika akan memerlukan kira-kira $4 bilion untuk melawan cacar monyet, wang yang "kami yakin bahawa kami boleh memanfaatkan," katanya. Kira-kira 200,000 dos akan mula diagihkan di negara-negara yang paling teruk terjejas dalam tempoh dua minggu akan datang, dan usaha sedang dilakukan untuk mendapatkan lebih daripada 10 juta dos yang dijangka akan diperlukan oleh benua itu pada akhirnya, menurut Kaseya. Langkah oleh CDC Afrika dibuat sehari sebelum panel penasihat yang ditubuhkan oleh dijangka mengadakan mesyuarat untuk membantu menentukan sama ada wabak maut itu merupakan kecemasan antarabangsa. WHO terakhir mengisytiharkan cacar monyet sebagai kecemasan kesihatan awam yang membimbangkan antarabangsa pada Mei 2022 ketika kes-kes jenis yang lebih ringan meletus di seluruh dunia, "tetapi Afrika tidak mendapat sokongan yang sewajarnya," kata Kaseya. Apabila agensi itu menurunkan tahap amarannya setahun kemudian, "kes di Afrika terus meningkat dan hari ini kita menghadapi akibat daripada tiada bantuan," katanya. CDC Afrika hanya diberi mandat untuk memanggil kecemasan kesihatan awam serantau pada tahun 2023, walaupun WHO memberi amaran ia juga boleh mencetuskan sekatan perjalanan dan perdagangan yang akan mengasingkan benua itu. Walau bagaimanapun, tidak ada alasan untuk menutup sempadan atau menghentikan perdagangan, kata Kaseya. “Apa yang kita lakukan sebelum ini tidak berkesan,” katanya. “Kami menyeru rakan kongsi antarabangsa kami untuk mengambil cacar monyet ini sebagai peluang untuk bertindak berbeza dan untuk bekerjasama rapat dengan CDC Afrika dan negara-negara Afrika untuk memberikan sokongan yang sewajarnya kepada orang yang terjejas.”Artikel ini disediakan oleh pembekal kandungan pihak ketiga. SeaPRwire (https://www.seaprwire.com/) tidak memberi sebarang waranti atau perwakilan berkaitan dengannya. Sektor: Top Story, Berita Harian SeaPRwire menyampaikan edaran siaran akhbar secara masa nyata untuk syarikat dan institusi, mencapai lebih daripada 6,500 kedai media, 86,000 penyunting dan wartawan, dan 3.5 juta desktop profesional di seluruh 90 negara. SeaPRwire menyokong pengedaran siaran akhbar dalam bahasa Inggeris, Korea, Jepun, Arab, Cina Ringkas, Cina Tradisional, Vietnam, Thai, Indonesia, Melayu, Jerman, Rusia, Perancis, Sepanyol, Portugis dan bahasa-bahasa lain.
More
Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results ACN Newswire

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results

August 14, 2024
Development Highlights- During the reporting Period, four of the Group’s innovative products were approved for marketing by the National Medical Products Administration of China (“NMPA”), namely Andewei (Benmelstobart Injection), Anboni (Unecritinib capsules), Anluoqing (Envonalkib capsules) and Beilelin (Liraglutide Injection), three of which are national category 1 innovative drugs.- In the first half of 2024, the Group's revenue from innovative products reached RMB 6.13 billion, a year-on-year increase of 14.8%. In addition to innovative products, the Group has 11 generic drugs approved by the NMPA for market launch. The overall revenue of generic drugs achieved positive growth in the first half of 2024. New products are an important driver of the Group’s revenue growth. In the first half of 2024, the Group’s revenue from new products launched within five years reached RMB 6.03 billion, representing a year-on-year increase of 39.6%.- As of 30 June 2024, the Group had a total of 43 innovative drug candidates in the field of oncology, 8 innovative drug candidates related to the respiratory system, 6 innovative drug candidates related to liver disease, and 4 innovative drug candidates in the field of surgery/analgesia in the process of clinical trial application or above. Of these, 3 innovative oncology drug candidates and 1 innovative surgery/analgesia drug candidate are in the marketing application stage, and 5 innovative oncology drug candidates, 1 innovative respiratory system drug candidate, 1 innovative liver disease drug candidate, and 1 innovative surgery/analgesia drug candidates are in Phase III clinical trials. In addition, the Group had a total of 18 biosimilar or generic drug oncology candidates, 3 additional biosimilar or generic liver disease drug candidates, 21 biosimilar or generic respiratory system drug candidates, and 10 biosimilar or generic surgical/analgesic drug candidates in the clinical trial application or above.- Focus V (Anlotinib Hydrochloride Capsules) is a new type of small molecule multi-target tyrosine kinase inhibitor. In February and July 2024, for anlotinib in combination with benmelstobart, two marketing applications were submitted to the Center for Drug Evaluation (“CDE”) of NMPA for the treatment of second- and third-line endometrial cancer, and first line renal cell carcinoma, respectively. In July 2024, the Phase III clinical study of anlotinib in combination with chemotherapy for the first-line treatment of advanced soft tissue sarcoma achieved positive results. The Group has submitted the marketing application and received acceptance for the new indication.- Yilishu (Efbemalenograstim Alfa Injection) was approved in May 2023 for the prevention and treatment of neutropenia in cancer patients taking chemotherapy drugs. In December 2023, Efbemalenograstim alfa was successfully included in the National Reimbursement Drug List (“NRDL”), and its sales volume accelerated in the first half of 2024, becoming an important contributor to the Group’s revenue growth.- Andewei (Benmelstobart Injection) is a humanized PD-L1 monoclonal antibody that was approved by the NMPA in April 2024 for use in combination with anlotinib, carboplatin, and etoposide in the first-line treatment of extensive-stage small cell lung cancer.- Anboni (Unecritinib Fumarate Capsules) is a small molecule inhibitor of tyrosine kinase ROS1/ALK/c-Met, which was approved by the NMPA in April 2024 for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer. It is the first domestically produced targeted drug approved for the treatment of ROS1-positive non-small cell lung cancer.- The clinical trial application of Lanifibranor was submitted to and accepted by CDE in March 2023. In July, Lanifibranor was included in the list of breakthrough therapeutics. Currently, Lanifibranor is conducting Phase III clinical trials globally and is actively advancing the enrollment of subjects. Lanifibranor is China's first oral MASH drug to enter Phase III clinical trials and is expected to fill the gap in China's MASH market.HONG KONG, Aug 14, 2024 - (ACN Newswire via SeaPRwire.com) - Sino Biopharmaceutical Limited (“Sino Biopharmaceutical” or the “Company”, together with its subsidiaries, the “Group”) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the “Period”).During the Period, the Group recorded revenue of approximately RMB15.87 billion, a year-on-year increase of approximately 11.1%. Profit attributable to owners of the parent company was approximately RMB3.02 billion, a year-on-year increase of approximately 139.7%. Earnings per share attributable to owners of the parent company were approximately RMB16.39 cents. The significant year-over-year increase in profit attributable to owners of the parent company was mainly due to the gain on disposal of subsidiaries under discontinued operations during the current Period. Adjusted non-HKFRS profit attributable to the owners of the parent was approximately RMB1.54 billion, a YOY increase of approximately 14.0%. The Group's liquidity remains strong, with cash and bank balances classified as current assets of approximately RMB8.55 billion, bank deposits classified as non-current assets of approximately RMB9.18 billion, and wealth management products of approximately RMB4.61 billion in total, and total fund reserves amounting to approximately RMB22.34 billion at the end of the Period.The Board of Directors has recommended an interim dividend payment of HK3 cents per share (1H2023: HK2 cents).Miss Tse, Theresa Y Y, Executive Director and ChairwomanSales: Entering harvesting of innovative results period and sales revenue from generic products further risesAlways placing utmost importance on research and development (“R&D”), the Group leverages in-depth research and development to achieve significant benefits. At present, the Group has entered the harvest period of its innovative development, driving further growth in sales revenue. During the Period, sales of oncology drugs increased by 19.5% year-on-year to approximately RMB5.36 billion, accounting for approximately 33.8% of the Group's revenue. Sales of surgical/analgesic medications increased by 29.9% year-on-year to approximately RMB2.58 billion, accounting for approximately 16.3% of the Group's revenue. Sales of liver disease drugs amounted to approximately RMB2.03 billion, accounting for approximately 12.8% of the Group's revenue. In addition, the sales contributions of products in various areas such as respiratory system, cardio-cerebral vascular medicines, and others increased simultaneously, accounting for approximately 11.2%, 8.6%, and 17.3% of the Group's total revenue, respectively.In the field of respiratory system, The Group has taken a series of proactive management measures in a timely manner, including strengthening downstream channels, expanding market coverage and conducting secondary development in markets outside the scope of the volume-based procurement (VBP), enabling Tianqing Suchang’s sales to achieve steady growth during the Period. In the meanwhile, the Group continued to expand its market coverage through active academic promotion, and Tianyun’s sales grew rapidly during the Period.In the field of surgery/analgesia, the Group focuses on the development of high-potential areas, further expanding its market coverage and gradually increasing its production capacity to meet the booming market demand. Sales of flurbiprofen cataplasms have maintained a growth trend in recent years and achieved breakthrough growth during the Period.Mr. Tse, Eric S Y, Executive Director and Chief Executive OfficerR&D: R&D as the core for driving the Group's continuous innovation and developmentThe Group has continued to focus its R&D efforts on new medicines in the four therapeutic areas of oncology, liver disease, respiratory system and surgery/analgesia. As at the end of the reporting Period, the Group had 76 innovative products in development, including 46 oncology products, 6 liver disease products, 9 respiratory system products, 5 surgery/analgesia products, and 10 other products. In addition, the Group had 65 generic drug products in development.The Group has always put R&D at its core, and has continuously improved its R&D capabilities and speed by embracing the R&D concept of combining independent innovation, collaborative development, and the development of both innovative and generic drugs. It considers R&D as the foundation of its sustainable development. In the first half of 2024, it incurred R&D expenses of approximately RMB 2.58 billion, accounting for approximately 16.2% of the Group’s revenue. It is expected that the number of innovative products launched to the market will reach 25 by 2026. This will further strengthen the Group’s dominant position in the four main therapeutic areas and provide strong impetus for long-term sustainable growth.Sino Biopharmaceutical ManagementProspects: Keep up with national development strategy and accelerate globalization processThe pharmaceutical industry has become one of the fastest growing and most promising fields in China and even the world. As the world’s second largest pharmaceutical market, China’s demand for medical and healthcare products has grown rapidly in recent years, with breakthroughs being made in biotechnology. Innovation has become a new driving force for the high-quality development of China’s pharmaceutical industry. The Group has been closely monitoring the development of the country, society and the industry, and has continuously optimized its development strategy. Under the four main strategies of “organizational integration, comprehensive innovation, internationalization, and digitalization”, the Group will actively innovate its organizational structure, comprehensively improve its operational efficiency, focus on the innovation and development of the four main therapeutic areas of oncology, liver disease, respiratory system, and surgery/analgesia, and actively accelerate the global deployment of its business.The Group is committed to its mission of becoming a “leading global pharmaceutical company through delivering innovative therapies for patients”. It strives to promote innovative development through its dual engines of internal R&D and business development. Over the years, the Group has stepped up its R&D investment and built strong internal R&D capabilities. At the same time, it has vigorously promoted business development and strategic cooperation, striving to become the best partner for global pharmaceutical and biotechnology enterprises. In April 2024, the Group entered into a strategic partnership with Boehringer Ingelheim to bring Boehringer Ingelheim's innovative cancer therapies to the Mainland Chinese market. This move not only demonstrates The Group's innovative strength in the pharmaceutical field, but also reflects its far-reaching influence in international cooperation.Looking ahead, The Group will adhere to its dual-pronged approach in the implementation of its globalization strategy. Through this approach, the Group will bring global pharmaceutical innovations to China to benefit Chinese patients, and also go global and open up new markets to accelerate the satisfaction of unmet clinical needs worldwide. Copyright 2024 ACN Newswire via SeaPRwire.com.
More